Brokerages Set Progyny, Inc. (NASDAQ:PGNY) Price Target at $33.91

Progyny, Inc. (NASDAQ:PGNY) has been assigned an average rating of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $33.9091.

A number of research firms recently weighed in on PGNY. BTIG Research lifted their target price on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Wall Street Zen cut Progyny from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Canaccord Genuity Group set a $35.00 price target on Progyny in a report on Friday, August 7th. Weiss Ratings upgraded Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, August 13th. Finally, Citizens Jmp lifted their price objective on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a report on Monday, May 11th.

Progyny Trading Up 0.5%

Shares of PGNY stock opened at $26.00 on Thursday. Progyny has a 1 year low of $16.10 and a 1 year high of $33.06. The firm’s fifty day simple moving average is $29.08 and its 200 day simple moving average is $23.63. The firm has a market capitalization of $1.99 billion, a P/E ratio of 28.26, a price-to-earnings-growth ratio of 1.79 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $349.05 million. During the same period in the prior year, the company earned $0.19 EPS. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Equities research analysts anticipate that Progyny will post 1.25 EPS for the current fiscal year.

Progyny declared that its Board of Directors has approved a share repurchase plan on Tuesday, May 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to purchase up to 10.3% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Insider Transactions at Progyny

In other Progyny news, Director Cheryl Scott sold 7,439 shares of Progyny stock in a transaction on Monday, June 1st. The shares were sold at an average price of $26.39, for a total transaction of $196,315.21. Following the sale, the director owned 19,772 shares in the company, valued at $521,783.08. The trade was a 27.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Geoffrey Clapp sold 1,530 shares of Progyny stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total transaction of $39,137.40. Following the sale, the insider owned 59,117 shares in the company, valued at $1,512,212.86. This represents a 2.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 13,563 shares of company stock valued at $351,968 in the last ninety days. 9.90% of the stock is owned by company insiders.

Institutional Trading of Progyny

Institutional investors have recently made changes to their positions in the business. Royal Bank of Canada lifted its stake in Progyny by 384.8% during the first quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock worth $291,000 after purchasing an additional 10,340 shares during the period. Amundi raised its holdings in shares of Progyny by 103.8% in the 1st quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after buying an additional 5,817 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Progyny by 6.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock worth $5,630,000 after buying an additional 14,297 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Progyny by 37.4% in the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock worth $8,342,000 after buying an additional 103,253 shares in the last quarter. Finally, Walleye Capital LLC lifted its position in shares of Progyny by 6.9% during the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock worth $266,000 after buying an additional 780 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.